AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

NMDAR

Summary

Peripherally acting NMDAR antagonists as new anti-diabetic medication. Novel approach for the reduction of blood sugar levels without risk of hypoglycaemia.

Technology Benefits

Novel approach for reduction of blood sugar levels without risk of Hypoglycaemia
Preclinical evidence of protection of insulin-secreting beta cells
Possible prevention or delay of diabetes Progression
Good results with starting substance in two clinical studies on human type 2 diabetics (Phase IIa)
Possible enhanced safety and reduced adverse effects compared to the OTC drug dextromethorphan

Technology Application

Antidiabetic Medication

Detailed Technology Description

DXO-derivatives that do not efficiently pass the blood brain barrier (BBB), and thus should cause fewer adverse effects on the CNS, but maintain their antidiabetic properties. Therefore, the derivatives might maintain the good safety profile and antidiabetic properties of its starting substance dextrorphan, but with fewer adverse effects.

Type of Cooperation

Licensing

Application Date

02/12/2016 00:00:00

Application No.

EP20160805448 20161202

Classes

- international:
A61K31/485; A61P25/00; A61P3/00; A61P35/00; C07D221/28; C07D401/04
- cooperative:
A61P3/10; C07D221/28; C07D401/04

Others

Patent application

ID No.

4501

Country/Region

Germany

For more information, please click Here